**Partial rescheduling of state-regulated medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An administrative hearing on broader rescheduling from Schedule I to Schedule III opened June 29, 2026, with a target conclusion by mid-July. The process stems from the 2024 proposed rule, public comments, and subsequent procedural resets that withdrew earlier hearing notices. Traders monitor the DEA’s post-hearing timeline for a final rule, any administrative law judge recommendations, and potential challenges or delays that could extend full implementation beyond 2026. Historical precedent shows administrative rescheduling can face extended reviews, while the current expedited track reflects explicit administration priorities on research access and state program alignment.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update$796,389 Vol.
Mar 31, 2026
September 30
14%
December 31
26%
$796,389 Vol.
September 30
$0 Vol.
14%
December 31
$186,818 Vol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-regulated medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An administrative hearing on broader rescheduling from Schedule I to Schedule III opened June 29, 2026, with a target conclusion by mid-July. The process stems from the 2024 proposed rule, public comments, and subsequent procedural resets that withdrew earlier hearing notices. Traders monitor the DEA’s post-hearing timeline for a final rule, any administrative law judge recommendations, and potential challenges or delays that could extend full implementation beyond 2026. Historical precedent shows administrative rescheduling can face extended reviews, while the current expedited track reflects explicit administration priorities on research access and state program alignment.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Binuksan ang Market: Feb 7, 2026, 5:04 PM ET
Volume
$796,389Petsa ng Pagtatapos
Mar 31, 2026Binuksan ang Market
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-regulated medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An administrative hearing on broader rescheduling from Schedule I to Schedule III opened June 29, 2026, with a target conclusion by mid-July. The process stems from the 2024 proposed rule, public comments, and subsequent procedural resets that withdrew earlier hearing notices. Traders monitor the DEA’s post-hearing timeline for a final rule, any administrative law judge recommendations, and potential challenges or delays that could extend full implementation beyond 2026. Historical precedent shows administrative rescheduling can face extended reviews, while the current expedited track reflects explicit administration priorities on research access and state program alignment.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$796,389Petsa ng Pagtatapos
Mar 31, 2026Binuksan ang Market
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Partial rescheduling of state-regulated medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An administrative hearing on broader rescheduling from Schedule I to Schedule III opened June 29, 2026, with a target conclusion by mid-July. The process stems from the 2024 proposed rule, public comments, and subsequent procedural resets that withdrew earlier hearing notices. Traders monitor the DEA’s post-hearing timeline for a final rule, any administrative law judge recommendations, and potential challenges or delays that could extend full implementation beyond 2026. Historical precedent shows administrative rescheduling can face extended reviews, while the current expedited track reflects explicit administration priorities on research access and state program alignment.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong